Revenues Tell The Story For BioHarvest Sciences Inc. (CSE:BHSC) As Its Stock Soars 26%

BioHarvest Sciences Inc. (CSE:BHSC) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. The last 30 days bring the annual gain to a very sharp 43%.

After such a large jump in price, when almost half of the companies in Canada's Personal Products industry have price-to-sales ratios (or "P/S") below 2.1x, you may consider BioHarvest Sciences as a stock not worth researching with its 5.5x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.

See our latest analysis for BioHarvest Sciences

What Does BioHarvest Sciences' P/S Mean For Shareholders?

Recent times have been advantageous for BioHarvest Sciences as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. If not, then existing shareholders might be a little nervous about the viability of the share price.

Want the full picture on analyst estimates for the company? Then our free report on BioHarvest Sciences will help you uncover what's on the horizon.

Is There Enough Revenue Growth Forecasted For BioHarvest Sciences?

The only time you'd be truly comfortable seeing a P/S as steep as BioHarvest Sciences' is when the company's growth is on track to outshine the industry decidedly.

If we review the last year of revenue growth, the company posted a terrific increase of 116%. This great performance means it was also able to deliver immense revenue growth over the last three years. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Turning to the outlook, the next year should generate growth of 141% as estimated by the one analyst watching the company. With the industry only predicted to deliver 3.6%, the company is positioned for a stronger revenue result.

With this in mind, it's not hard to understand why BioHarvest Sciences' P/S is high relative to its industry peers. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

What We Can Learn From BioHarvest Sciences' P/S?

BioHarvest Sciences' P/S has grown nicely over the last month thanks to a handy boost in the share price. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

As we suspected, our examination of BioHarvest Sciences' analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. At this stage investors feel the potential for a deterioration in revenues is quite remote, justifying the elevated P/S ratio. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.

You need to take note of risks, for example - BioHarvest Sciences has 3 warning signs (and 2 which are a bit unpleasant) we think you should know about.

It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.